Farnesyltransferase inhibitor tipifarnib inhibits rheb prenylation and stabilizes bax in acute myelogenous leukemia cells

Husheng Ding, Jennifer S McDonald, Seongseok Yun, Paula A. Schneider, Kevin L. Peterson, Karen S. Flatten, David A. Loegering, Ann L Oberg, Shaun M. Riska, Shengbing Huang, Frank A Sinicrope, Alex Adjei, Judith E. Karp, X. Wei Meng, Scott H Kaufmann

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Although farnesyltransferase inhibitors have shown promising activity in relapsed lymphoma and sporadic activity in acute myelogenous leukemia, their mechanism of cytotoxicity is incompletely understood, making development of predictive biomarkers difficult. In the present study, we examined the action of tipifarnib in human acute myel-ogenous leukemia cell lines and clinical samples. In contrast to the Ras/MEK/ERK pathway-mediated Bim upregu-lation that is responsible for tipifarnib-induced killing of malignant lymphoid cells, inhibition of Rheb-induced mTOR signaling followed by dose-dependent upregulation of Bax and Puma occurred in acute myelogenous leukemia cell lines undergoing tipifarnib-induced apoptosis. Similar Bax and Puma upregulation occurred in serial bone marrow samples harvested from a subset of acute myelogenous leukemia patients during tipifarnib treatment. Expression of FTI-resistant Rheb M184L, like knockdown of Bax or Puma, diminished tipifarnib-induced killing. Further analysis demonstrated that increased Bax and Puma levels reflect protein stabilization rather than increased gene expression. In U937 cells selected for tipifarnib resistance, neither inhibition of signaling downstream of Rheb nor Bax and Puma stabilization occurred. Collectively, these results not only identify a pathway downstream from Rheb that contributes to tipifarnib cytotoxicity in human acute myelogenous leukemia cells, but also demonstrate that FTI-induced killing of lymphoid versus myeloid cells reflects distinct biochemical mechanisms downstream of different farnesylated substrates.

Original languageEnglish (US)
Pages (from-to)60-69
Number of pages10
JournalHaematologica
Volume99
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

tipifarnib
Farnesyltranstransferase
Prenylation
Puma
Acute Myeloid Leukemia
Up-Regulation
Cell Line
U937 Cells
MAP Kinase Signaling System
Myeloid Cells
Lymphoma
Leukemia
Biomarkers
Bone Marrow
Lymphocytes
Apoptosis
Gene Expression

ASJC Scopus subject areas

  • Hematology

Cite this

Farnesyltransferase inhibitor tipifarnib inhibits rheb prenylation and stabilizes bax in acute myelogenous leukemia cells. / Ding, Husheng; McDonald, Jennifer S; Yun, Seongseok; Schneider, Paula A.; Peterson, Kevin L.; Flatten, Karen S.; Loegering, David A.; Oberg, Ann L; Riska, Shaun M.; Huang, Shengbing; Sinicrope, Frank A; Adjei, Alex; Karp, Judith E.; Meng, X. Wei; Kaufmann, Scott H.

In: Haematologica, Vol. 99, No. 1, 01.01.2014, p. 60-69.

Research output: Contribution to journalArticle

Ding, Husheng ; McDonald, Jennifer S ; Yun, Seongseok ; Schneider, Paula A. ; Peterson, Kevin L. ; Flatten, Karen S. ; Loegering, David A. ; Oberg, Ann L ; Riska, Shaun M. ; Huang, Shengbing ; Sinicrope, Frank A ; Adjei, Alex ; Karp, Judith E. ; Meng, X. Wei ; Kaufmann, Scott H. / Farnesyltransferase inhibitor tipifarnib inhibits rheb prenylation and stabilizes bax in acute myelogenous leukemia cells. In: Haematologica. 2014 ; Vol. 99, No. 1. pp. 60-69.
@article{330691f12d804f4885959a1380d44d38,
title = "Farnesyltransferase inhibitor tipifarnib inhibits rheb prenylation and stabilizes bax in acute myelogenous leukemia cells",
abstract = "Although farnesyltransferase inhibitors have shown promising activity in relapsed lymphoma and sporadic activity in acute myelogenous leukemia, their mechanism of cytotoxicity is incompletely understood, making development of predictive biomarkers difficult. In the present study, we examined the action of tipifarnib in human acute myel-ogenous leukemia cell lines and clinical samples. In contrast to the Ras/MEK/ERK pathway-mediated Bim upregu-lation that is responsible for tipifarnib-induced killing of malignant lymphoid cells, inhibition of Rheb-induced mTOR signaling followed by dose-dependent upregulation of Bax and Puma occurred in acute myelogenous leukemia cell lines undergoing tipifarnib-induced apoptosis. Similar Bax and Puma upregulation occurred in serial bone marrow samples harvested from a subset of acute myelogenous leukemia patients during tipifarnib treatment. Expression of FTI-resistant Rheb M184L, like knockdown of Bax or Puma, diminished tipifarnib-induced killing. Further analysis demonstrated that increased Bax and Puma levels reflect protein stabilization rather than increased gene expression. In U937 cells selected for tipifarnib resistance, neither inhibition of signaling downstream of Rheb nor Bax and Puma stabilization occurred. Collectively, these results not only identify a pathway downstream from Rheb that contributes to tipifarnib cytotoxicity in human acute myelogenous leukemia cells, but also demonstrate that FTI-induced killing of lymphoid versus myeloid cells reflects distinct biochemical mechanisms downstream of different farnesylated substrates.",
author = "Husheng Ding and McDonald, {Jennifer S} and Seongseok Yun and Schneider, {Paula A.} and Peterson, {Kevin L.} and Flatten, {Karen S.} and Loegering, {David A.} and Oberg, {Ann L} and Riska, {Shaun M.} and Shengbing Huang and Sinicrope, {Frank A} and Alex Adjei and Karp, {Judith E.} and Meng, {X. Wei} and Kaufmann, {Scott H}",
year = "2014",
month = "1",
day = "1",
doi = "10.3324/haematol.2013.087734",
language = "English (US)",
volume = "99",
pages = "60--69",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "1",

}

TY - JOUR

T1 - Farnesyltransferase inhibitor tipifarnib inhibits rheb prenylation and stabilizes bax in acute myelogenous leukemia cells

AU - Ding, Husheng

AU - McDonald, Jennifer S

AU - Yun, Seongseok

AU - Schneider, Paula A.

AU - Peterson, Kevin L.

AU - Flatten, Karen S.

AU - Loegering, David A.

AU - Oberg, Ann L

AU - Riska, Shaun M.

AU - Huang, Shengbing

AU - Sinicrope, Frank A

AU - Adjei, Alex

AU - Karp, Judith E.

AU - Meng, X. Wei

AU - Kaufmann, Scott H

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Although farnesyltransferase inhibitors have shown promising activity in relapsed lymphoma and sporadic activity in acute myelogenous leukemia, their mechanism of cytotoxicity is incompletely understood, making development of predictive biomarkers difficult. In the present study, we examined the action of tipifarnib in human acute myel-ogenous leukemia cell lines and clinical samples. In contrast to the Ras/MEK/ERK pathway-mediated Bim upregu-lation that is responsible for tipifarnib-induced killing of malignant lymphoid cells, inhibition of Rheb-induced mTOR signaling followed by dose-dependent upregulation of Bax and Puma occurred in acute myelogenous leukemia cell lines undergoing tipifarnib-induced apoptosis. Similar Bax and Puma upregulation occurred in serial bone marrow samples harvested from a subset of acute myelogenous leukemia patients during tipifarnib treatment. Expression of FTI-resistant Rheb M184L, like knockdown of Bax or Puma, diminished tipifarnib-induced killing. Further analysis demonstrated that increased Bax and Puma levels reflect protein stabilization rather than increased gene expression. In U937 cells selected for tipifarnib resistance, neither inhibition of signaling downstream of Rheb nor Bax and Puma stabilization occurred. Collectively, these results not only identify a pathway downstream from Rheb that contributes to tipifarnib cytotoxicity in human acute myelogenous leukemia cells, but also demonstrate that FTI-induced killing of lymphoid versus myeloid cells reflects distinct biochemical mechanisms downstream of different farnesylated substrates.

AB - Although farnesyltransferase inhibitors have shown promising activity in relapsed lymphoma and sporadic activity in acute myelogenous leukemia, their mechanism of cytotoxicity is incompletely understood, making development of predictive biomarkers difficult. In the present study, we examined the action of tipifarnib in human acute myel-ogenous leukemia cell lines and clinical samples. In contrast to the Ras/MEK/ERK pathway-mediated Bim upregu-lation that is responsible for tipifarnib-induced killing of malignant lymphoid cells, inhibition of Rheb-induced mTOR signaling followed by dose-dependent upregulation of Bax and Puma occurred in acute myelogenous leukemia cell lines undergoing tipifarnib-induced apoptosis. Similar Bax and Puma upregulation occurred in serial bone marrow samples harvested from a subset of acute myelogenous leukemia patients during tipifarnib treatment. Expression of FTI-resistant Rheb M184L, like knockdown of Bax or Puma, diminished tipifarnib-induced killing. Further analysis demonstrated that increased Bax and Puma levels reflect protein stabilization rather than increased gene expression. In U937 cells selected for tipifarnib resistance, neither inhibition of signaling downstream of Rheb nor Bax and Puma stabilization occurred. Collectively, these results not only identify a pathway downstream from Rheb that contributes to tipifarnib cytotoxicity in human acute myelogenous leukemia cells, but also demonstrate that FTI-induced killing of lymphoid versus myeloid cells reflects distinct biochemical mechanisms downstream of different farnesylated substrates.

UR - http://www.scopus.com/inward/record.url?scp=84892603452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892603452&partnerID=8YFLogxK

U2 - 10.3324/haematol.2013.087734

DO - 10.3324/haematol.2013.087734

M3 - Article

VL - 99

SP - 60

EP - 69

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 1

ER -